Does postoperative thyrotropin suppression therapy truly decrease recurrence in papillary thyroid carcinoma? A randomized controlled trial

Journal of Clinical Endocrinology and Metabolism

Volumn 95, Issue 10, 2010, Pages 4576-4583

  Sugitani, Iwao ^a   Fujimoto, Yoshihide ^a  

^a CANCER INSTITUTE HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

LEVOTHYROXINE; LIOTHYRONINE; THYROGLOBULIN; THYROTROPIN; THYROXINE;

ADOLESCENT; ADULT; AGE; AGED; ANGINA PECTORIS; ARTICLE; CANCER HORMONE THERAPY; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; ECHOGRAPHY; FEMALE; HAZARD RATIO; HEART ATRIUM FIBRILLATION; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; MORNING DOSAGE; OPEN STUDY; PAPILLARY THYROID CARCINOMA; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; RECURRENT CANCER; SINGLE DRUG DOSE; THYROGLOBULIN BLOOD LEVEL; THYROID CARCINOMA; THYROIDECTOMY; THYROTOXICOSIS; THYROTROPIN BLOOD LEVEL;

EID: 77957801614     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2010-0161     Document Type: Article

References (40)

1. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F, Schlumberger M, Sherman SI, Steward DL, Tuttle RM 2009 Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19:1167-1214
2. AACE/AME Task Force on Thyroid Nodules 2006 American Association of Clinical Endocrinologists and Associazione Medici Endocrinologi medical guidelines for clinical practice for the diagnosis and management of thyroid nodules. Endocr Pract 12:63-102
3. Shigematsu N, Takami H, Kubo A 2006 Unique treatment policy for well-differentiated thyroid cancer in Japan: results of a questionnaire distributed to members of the Japanese Society of Thyroid Surgery and the International Association of Endocrine Surgeons. Endocr J 53:829-839
4. Sugitani I, Fujimoto Y 2010 Management of low-risk papillary thyroid carcinoma: unique conventional policy in Japan and our efforts to improve the level of evidence. Surg Today 40:199-215
5. Ichikawa Y, Saito E, Abe Y, Homma M, Muraki T, Ito K 1976. Presence of TSH receptor in thyroid neoplasms. J Clin Endocrinol Metab 42:395-398
6. Dunhill TP 1937 The surgery of the thyroid gland: the Lettsomian lectures. Trans Med Soc Lond 60:234-282
7. Mazzaferri EL, Young RL, Oertel JE, Kemmerer WT, Page CP 1977 Papillary thyroid carcinoma: the impact of therapy in 576 patients. Medicine 56:171-196
8. Crile Jr G 1971 Changing end results in patients with papillary carcinoma of the thyroid. Surg Gynecol Obstet 132:460-468
9. Young RL, Mazzaferri EL, Rahe AJ, Dorfman SG 1980 Pure follicular thyroid carcinoma: impact of therapy in 214 patients. J Nucl Med 21:733-737
10. Wanebo HJ, Andrews W, Kaiser DL 1981 Thyroid cancer: some basic considerations. Am J Surg 142:474-479
11. Cady B, Cohn K, Rossi RL, Sedgwick CE, Meissner WA, Werber J, Gelman RS 1983 The effect of thyroid hormone administration upon survival in patients with differentiated thyroid carcinoma. Surgery 94:978-983
12. Rossi RL, Cady B, Silverman ML, Wool MS, ReMine SG, Hodge MB, Salzman FA 1988 Surgically incurable well-differentiated thyroid carcinoma. Prognostic factors and results of therapy. Arch Surg 123:569-574
13. Mazzaferri EL, Jhiang SM 1994 Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer.Am J Med 97:418-428
14. Sanders LE, Rossi RL 1995 Occult well differentiated thyroid carcinoma presenting as cervical node disease. World J Surg 19:642-647
15. Pujol P, Daures JP, Nsakala N, Baldet L, Bringer J, Jaffiol C 1996 Degree of thyrotropin suppression as a prognostic determinant in differentiated thyroid cancer. J Clin Endocrinol Metab 81:4318-4323
16. Cooper DS, Specker B, Ho M, Sperling M, Ladenson PW, Ross DS, Ain KB, Bigos ST, Brierley JD, Haugen BR, Klein I, Robbins J, Sherman SI, Taylor T, Maxon 3rd HR 1998 Thyrotropin suppression and disease progression in patients with differentiated thyroid cancer: results from the National Thyroid Cancer Treatment Cooperative Registry. Thyroid 8:737-744
17. Hovens GC, Stokkel MP, Kievit J, Corssmit EP, Pereira AM, Romijn JA, Smit JW 2007 Association of serum thyrotropin concentration with recurrence and death in differentiated thyroid cancer. J Clin Endocrinol Metab 92:2610-2615
18. Kamel N, Güllü S, Daoci Ilgin S, Corapçioolu D, Tonyukuk Cesur V, Uysal AR, Bapkal N, Erdooan G 1999 Degree of thyrotropin suppression in differentiated thyroid cancer without recurrence or metastases. Thyroid 9:1245-1248
19. Cady B, Rossi R 1988 An expanded view of risk group definition in differentiated thyroid carcinoma. Surgery 104:947-953
20. McGriff NJ, Csako G, Gourgiotis L, Lori C G, Pucino F, Sarlis NJ 2002 Effects of thyroid hormone suppression therapy on adverse clinical outcomes in thyroid cancer. Ann Med 34:554-564
21. Sugitani I, Kasai N, Fujimoto Y, Yanagisawa A 2004 A novel classification system for patients with PTC: addition of the new variables of large (3 cm or greater) nodal metastases and reclassification during the follow-up period. Surgery 135:139-148
22. Udelsman R, Lakatos E, Ladenson P 1996 Optimal surgery for papillary thyroid carcinoma. World J Surg 20:88-93
23. Carayon P, Thomas-Morvan C, Castanas E, Tubiana M 1980 Human thyroid cancer: membrane thyrotropin binding and adenylate cyclate activity. J Clin Endocrinol Metab 51:915-920
24. Bruno R, Ferretti E, Tosi E, Arturi F, Giannasio P, Mattei T, Scipioni A, Presta I, Morisi R, Gulino A, Filetti S, Russo D 2005 Modulation of thyroid-specific gene expression in normal and nodular human thyroid tissues from adults: an in vivo effect of thyrotropin. J Clin Endocrinol Metab 90:5692-5697
25. Boelaert K, Horacek J, Holder RL, Watkinson JC, Sheppard MC, Franklyn JA 2006 Serum thyrotropin concentration as a novel predictor of malignancy in thyroid nodules investigated by fine-needle aspiration. J Clin Endocrinol Metab 91:4295-4301
26. Haymart MR, Repplinger DJ, Leverson GE, Elson DF, Sippel RS, Jaume JC, Chen H 2008 Higher serum TSH level in thyroid nodule patients is associated with greater risks of differentiated thyroid cancer and advanced tumor stage. J Clin Endocrinol Metab 93:809-814
27. Fiore E, Rago T, Provenzale MA, Scutari M, Ugolini C, Basolo F, Di Coscio G, Berti P, Grasso L, Elisei R, Pinchera A, Vitti P 2009 Lower levels of TSH are associated with a lower risk of papillary thyroid cancer in patients with thyroid nodular disease: thyroid autonomy may play a predictive role. Endocr Relat Cancer 16:1251-1260
28. Furukawa MK, Furukawa M 2010 Diagnosis of lymph node metastasis of head and neck cancer and evaluation of effects of chemoradiotherapy using ultrasonography. Int J Clin Oncol 15:23-32
29. Sugitani I, Fujimoto Y, Yamada K, Yamamoto N 2008 Prospective outcomes of selective lymph node dissection for papillary thyroid carcinoma based on preoperative ultrasonography. World J Surg 32:2494-2502
30. Kloos RT, Mazzaferri EL 2005 A single recombinant human thyrotropin-stimulated serum thyroglobulin measurement predicts differentiated thyroid carcinoma metastases three to five years later. J Clin Endocrinol Metab 90:5047-5057
31. Mazzaferri EL, Robbins RJ, Spencer CA, Braverman LE, Pacini F, Wartofsky L, Haugen BR, Sherman SI, Cooper DS, Braunstein GD, Lee S, Davies TF, Arafah BM, Ladenson PW, Pinchera A 2003 Author's response: a consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J Clin Endocrinol Metab 88:4508-4510
32. Mittendorf EA, Wang X, Perrier ND, Francis AM, Edeiken BS, Shapiro SE, Lee JE, Evans DB 2007 Followup of patients with papillary thyroid cancer: in search of the optimal algorithm. J Am Coll Surg 205:239-247
33. Fish LH, Schwartz HL, Cavanaugh J, Steffes MW, Bantle JP, Oppenheimer JH 1987 Replacement dose, metabolism, and bioavailability of levothyroxine in the treatment of hypothyroidism. Role of triiodothyronine in pituitary feedback in humans. N Engl J Med 316:764-770
34. Oda M 1979 [Hormone therapy in postoperative cases of differentiated thyroid cancer]. Nippon Geka Gakkai Zassi 80:32-41 (Japanese)
35. Biondi B, Filetti S, Schlumberger M 2005 Thyroid-hormone therapy and thyroid cancer: a reassessment. Nat Clin Pract Endocrinol Metab 1:32-40
36. Sawin CT, Geller A, Wolf PA, Belanger AJ, Baker E, Bacharach P, Wilson PW, Benjamin EJ, D'Agostino RB 1994 Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. N Engl J Med 331:1249-1252
37. Cobin RH 1995 Thyroid hormone excess and bone: a clinical review. Endocr Pract 1:404-409
38. Burman KD 1995 How serious are the risks of thyroid hormone over-replacement? Thyroid Today 18:1-9
39. Jonklaas J, Sarlis NJ, Litofsky D, Ain KB, Bigos ST, Brierley JD, Cooper DS, Haugen BR, Ladenson PW, Magner J, Robbins J, Ross DS, Skarulis M, Maxon HR, Sherman SI 2006 Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid 16:1229-1242
40. Cady B 1998 Presidential address: beyond risk groups: a new look at differentiated thyroid cancer. Surgery 124:947-957